-
In an interview with CNBC-TV18, Surya Patra, Vice President Pharma - Institutional Equity Research at Phillipcapital, says that the company has cut its FY17 estimates for Sun Pharma by 5 percent.
-
Saumen Chakraborty, CFO, Dr Reddy's Laboratories, says "The warning letter has come telling the management to respond within 15 working days in terms of strategy and plan."
-
Surya Narayan Patra of Phillipcapital says the news on Elepsia is more relevant to Sun Pharma. The product was linked to one of the facilities linked to USFDA issues
-
Speaking on acquisitions, Satish Reddy, Chairman of Dr Reddy's said they are always on the lookout for strategic fits to boost growth.
-
In an interview with CNBC-TV18's Archana Shukla and Nayantara Rai, Saumen Chakraborty, India - President, CFO and Global IT Head, Dr Reddy's Laboratories, discussed the company's first quarter earnings.
-
Dr Reddy's Labs has posted a consolidated net profit of Rs 519 crore in the quarter ended March 2015 up 7.8 percent from Rs 481.6 crore in the corresponding quarter last fiscal. During the period, total income was up 11.2 percent at Rs 3870 crore versus Rs 3481 crore (Y-o-Y) on consolidated basis.
-
According to Alok Sonig of DRL, the acquired brands have grown historically at lower double-digits and have a lot of headroom to grow further
-
The company has 20 facilities across the globe with portfolio of more than 200 products in 138 countries.
-
Dr Reddy's Laboratories beat street expectations on both topline and bottomline but operating performance was below estimates. Consolidated net profit of the drug maker fell 7 percent year-on-year to Rs 574.5 crore, impacted by weak operational performance and higher R&D expenses.
-
GV Prasad, Co-Chairman & CEO of Dr Reddy‘s Laboratories said a lot of growth is seen in emerging markets
-
As 2014 comes to an end, Surajit Pal of Prabhudas Lilladher shares his outlook on the year that was and the possible trends for 2015.
-
Ranbaxy has first-to-file status, meaning eligibility for six months of generic sales exclusivity for both AstraZeneca's heartburn drug Nexium & Roche's antiviral drug Valcyte drugs. However, the final approvals for these drugs were delayed because of the compliance issues at Ranbaxy's plants.
-
Discussing the company‘s results, GV Prasad co-chairman and CEO, DRL, said the quarter has been a flattish one on the back of high R&D expenses. He expects growth to return once launches start happening.
-
The DRL-GSK deal was to sell branded generic formulations in emerging markets and was entered into in 2009.
-
Dr Reddy's Labs has signed an agreement with Galena Biopharma to develop NeuVax in India.
-
Umang Vohra, executive VP and CFO, Dr Reddy‘s Laboratories explains to CNBC-TV18 that product launches have caused the surge in the pharma giant's quarterly EBITDA.
-
GV Prasad VC & CEO, Dr Reddy Laboratories explains to CNBC-TV18 that the reason for company‘s good performance for the quarter is the robust growth in the US, Russia and the API business
-
Dr Reddy’s also has slew of significant new launches lined-up ahead. It would also be launching a biosimilar product every year beginning with the Indian market. These products are expected to drive company's near-term growth.
-
G V Prasad, VC & CEO, Dr Reddy's Laboratories tells CNBC-TV18 that North America, Russia and the Pharmaceuticals Services and Active Ingredients (PSAI) segment led to the stupendous growth in the business.
-
Leading global pharmaceutical company JB Chemical has sold its prescription business to Dr Reddy's for USD 35 million. In an exclusive interview with CNBC-TV18, the company’s president, Pranabh Mody says a significant part of the cash earned from the sell will be used to reward shareholders.
-
In an interview with CNBC-TV18, GV Prasad, vice-chairman & CEO of DRL spoke about the company's quarterly performance and future plans.
-
GV Prasad, Vice Chairman and CEO, Dr Reddys Laboratories in an interview with CNBC-TV18 spoke about the quarterly numbers of the company and the road ahead.
-
Speaking to CNBC-TV18 on the quarter gone by, GV Prasad, Vice Chairman & CEO, Dr Reddy Laboratories said operating expenses have increased due to one-time litigation costs.
-
Kamal Sharma, Managing Director of Lupin, started four decades ago almost as a stockiest and C&F agent. Today, his company is one of India’s largest drug manufacturers and the 5th largest generic drug manufacturer in the world.
-
Drug majors Ranbaxy and Merck have called off a deal that would have seen both the pharma giants join hands to research anti-infectives, reports PharmAsia News. The deal between the two companies was struck in 2008. Ranbaxy was to get milestones and an undisclosed upfront fee as part of the deal.
